Market Overview

Roth Capital Downgrades PTC Therapeutics To Neutral


Analysts at Roth Capital downgraded PTC Therapeutics, Inc. (NASDAQ: PTCT) from Buy to Neutral.

The price target for PTC Therapeutics has been lowered from $75.00 to $63.00.

PTC Therapeutics shares have gained 248.85 percent over the past 52 weeks, while the S&P 500 index has surged 13.21 percent in the same period.

PTC Therapeutics' shares fell 4.34 percent to $58.20 in after-hours trading.

Latest Ratings for PTCT

Apr 2019Initiates Coverage OnOutperform
Nov 2018MaintainsOverweightOverweight
Nov 2018MaintainsOutperformOutperform

View More Analyst Ratings for PTCT
View the Latest Analyst Ratings

Posted-In: Roth CapitalDowngrades Analyst Ratings


Related Articles (PTCT)

View Comments and Join the Discussion!

Latest Ratings

View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

U.S. Dollar Little Lower

Disney Tops Q2 Views, Shares Gain